Oesophageal Cancer Trial, Recruiting NCT03222635 Sponsor: Amsterdam UMC Condition: Oesophageal Cancer
Back to Oesophageal Cancer

Oesophageal Cancer Trial, Recruiting

NCT03222635
Recruiting Not Applicable 🇦🇺 Australian site

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • People who have been diagnosed with a specific type of oesophageal cancer (called early oesophageal adenocarcinoma) that is either in the deeper layer under the lining of the oesophagus, or is a higher-risk surface-level cancer, as confirmed by a specialist digestive system pathologist examining a tissue sample removed during a procedure.
  • People who are willing and able to sign a consent form agreeing to take part in the trial.

Who may not be able to join:

  • People who have previously been treated for a higher-risk surface-level or deeper oesophageal adenocarcinoma of the same type.
  • People who also have a different type of oesophageal cancer called squamous cell carcinoma at the same time.
  • People where scans or ultrasound examinations (performed within six weeks of the tissue removal procedure) show any sign that the cancer may have spread to nearby lymph nodes or other parts of the body.
  • People whose tissue sample showed that cancer cells were present at the deepest edge of the removed tissue, meaning the cancer may not have been fully removed.
  • People who are unable to sign a consent form agreeing to take part.

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 23 July 2026
This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Contact this trial

Principal Investigator: J. J. Bergman, MD, PhD, Amsterdam UMC

Phone: +31204445500

Australian sites

Westmead hospital, Sydney,

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Not Applicable
Sponsor
Amsterdam UMC
Registry
ClinicalTrials.gov
Start date
25 July 2017
Est. completion
25 July 2028

Where this trial is recruiting

🇦🇺 Australia 🇧🇪 Belgium 🇩🇪 Germany 🇳🇱 Netherlands 🇨🇭 Switzerland 🇬🇧 United Kingdom

1 site(s) in Australia. Confirm current status and contact details directly with the trial site.

Primary endpoints

5-year disease-specific mortality/survival (descriptive statistics in SPSS, percentages, survival analysis); Overall survival (descriptive statistics in SPSS, percentages, survival analysis)

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 23 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov